San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor during the weight loss drug market place in February just after revealing promising information from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as